<p>Parkinson’s disease (PD) is a multifaceted neurodegenerative disorder driven by a complex interplay of genetic and environmental factors that disrupt normal cellular function. A hallmark of PD pathology is the abnormal accumulation of alpha-synuclein protein, leading to the formation of Lewy Bodies and the degeneration of dopaminergic neurons. Critical proteins like Akt1 and glycogen synthase kinase-3 beta (GSK-3β) are vital for cell survival and apoptosis regulation; their dysfunction adversely affects the health of dopaminergic neurons, accelerating neurodegeneration. Additionally, PARK2 (parkin) and PTEN-induced kinase 1 (PINK1) are crucial for mitochondrial function and energy homeostasis. In PD, mutations in these genes are reported and impair mitochondrial quality control, making neurons more vulnerable to stress and exacerbating disease progression. The enzyme glucocerebrosidase (GBA), crucial for lysosomal function, is also linked to PD, with mutations in the GBA gene associated with increased SNCA accumulation and faster disease progression. Interestingly, tau protein, typically associated with Alzheimer’s Disease, is also present in Parkinson’s disease pathology, suggesting a potential overlap in the mechanisms driving these neurodegenerative diseases. The vesicular monoamine transporter 2 (VMAT2) plays a crucial role in dopamine regulation, and its malfunction can render dopaminergic neurons more vulnerable to degeneration. In conclusion, PD represents a complex interplay of genetic, protein-related, and environmental factors leading to progressive neurodegeneration. Understanding these molecular mechanisms is crucial for developing biomarkers and advanced therapies. Ongoing research is essential for creating treatments that effectively manage symptoms, slow disease progression, and improve patient quality of life, ultimately transforming the lives of those affected.</p>